Servier

Precision reacquires rights to allogeneic CAR-Ts from Servier
Precision reacquires rights to allogeneic CAR-Ts from Servier
Fierce Biotech
Precision Biosciences
allogeneic cells
CAR-T
Servier
Flag link:
Agios, changing its identity, to sell cancer drug business to Servier
Agios, changing its identity, to sell cancer drug business to Servier
BioPharma Dive
Agios Pharmaceuticals
cancer
M&A
Servier
Flag link:
Colorectal drug candidates focal point of new collaboration between Servier, Celsius Therapeutics
Colorectal drug candidates focal point of new collaboration between Servier, Celsius Therapeutics
Endpoints
Servier
Celsius Therapeutics
colorectal cancer
drug discovery
Flag link:
Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal
Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal
Fierce Biotech
Galapagos
Servier
GLPG1972
osteoarthritis of the knee
clinical trials
Flag link:
Amgen and Cytokinetics claim heart drug success, but results widely disappoint
Amgen and Cytokinetics claim heart drug success, but results widely disappoint
BioPharma Dive
Amgen
Cytokinetics
Servier
clinical trials
Omecamtiv Mecarbil
cardiovascular disease
Flag link:
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
AP
Servier
R&D
Symphogen
antibodies
Flag link:
Trial of Amgen, Servier’s heart failure drug clears interim check
Trial of Amgen, Servier’s heart failure drug clears interim check
PM Live
Amgen
Servier
chronic heart failure
Omecamtiv Mecarbil
clinical trials
Flag link:
Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier
Endpoints
CAR-T
Cellectis
Servier
UCART19
Flag link:
Servier reveal how they are using data to empower their field force
Servier reveal how they are using data to empower their field force
Pharmaforum
Servier
drug reps
CRM
digital pharma
Flag link:
Servier acquires lymphoma drug Pixuvri from CTI BioPharma
Servier acquires lymphoma drug Pixuvri from CTI BioPharma
Pharmaceutical Business Review
Pixuvri
Servier
CTI BioPharma
M&A
lymphoma
Flag link:
Servier begins manslaughter trial over weight loss drug
Servier begins manslaughter trial over weight loss drug
Endpoints
Servier
patient deaths
weight loss
Mediator
Flag link:
Companies file suit in Canada challenging new rules to lower drug prices
Companies file suit in Canada challenging new rules to lower drug prices
Yahoo/Reuters
drug pricing
Canada
Janssen
Merck
Bayer
Servier
Boehringer Ingelheim
Flag link:
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer
Pharmaceutical Business Review
Ipsen
Servier
liposomal irinotecan
pancreatic cancer
Flag link:
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Servier, armed with Shire cancer drugs, builds out vision for U.S. future
Fierce Pharma
Servier
oncology
Shire
M&A
Flag link:
Amgen, Servier heart failure drug clears trial hurdle
Amgen, Servier heart failure drug clears trial hurdle
PM Live
Amgen
Servier
heart failure
Omecamtiv Mecarbil
clinical trials
Flag link:
Servier and Oncodesign announce Parkinson’s R&D tie-up
Servier and Oncodesign announce Parkinson’s R&D tie-up
Pharmaforum
Servier
Oncodesign
R&D
Parkinson's Disease
Flag link:
Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure
Amgen and partners begin second phase 3 trial of omecamtiv mecarbil in patients with heart failure
Pharmaceutical Business Review
Amgen
heart failure with reduced ejection fraction
Omecamtiv Mecarbil
Cytokinetics
Servier
Flag link:
FDA approves Servier's ALL therapy, acquired in Shire deal
FDA approves Servier's ALL therapy, acquired in Shire deal
BioCentury
FDA
SHP663
Servier
ALL
Flag link:
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Servier drops GeNeuro’s multiple sclerosis drug after midphase miss
Fierce Biotech
Servier
GeNeuro
MS
multiple sclerosis
GNbAC1
Flag link:
Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer
Phase III Trial Data Demonstrates Significant Overall Survival Benefit of Lonsurf (trifluridine and tipiracil) in Patients with Metastatic Gastric Cancer
CP Wire
Servier
Taiho Pharmaceutical
Lonsurf
gastric cancer
Flag link:

Pages